Rituximab 375 mg/m2weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50×109/L) and complete responses (platelet count > 100×109/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose. ©2008 Ferrata Storti Foundation.
|Titolo:||Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura|
|Citazione:||Zaja, F., Battista, M.L., Pirrotta, M.T., Palmieri, S., Montagna, M., Vianelli, N., et al. (2008). Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. HAEMATOLOGICA, 93(6), 930-933.|
|Appare nelle tipologie:||1.1 Articolo in rivista|